These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 20015242)

  • 21. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
    Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
    Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma.
    Wang ES; Straus DJ; Teruya-Feldstein J; Qin J; Portlock C; Moskowitz C; Goy A; Hedrick E; Zelenetz AD; Noy A
    Cancer; 2003 Sep; 98(6):1196-205. PubMed ID: 12973843
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A dose escalation study for salvage chemotherapy in patients with refractory lymphoma prior to high-dose myeloablative therapy with stem cell transplantation.
    Lee CK; de Magalhaes-Silverman M; Hayashi M; Schlueter A; Strauss RG; Hohl RJ; Gingrich RD
    Bone Marrow Transplant; 2002 Apr; 29(8):647-52. PubMed ID: 12180108
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase I study of ifosfamide/carboplatin/etoposide/paclitaxel in advanced lung cancer.
    Strauss GM; Lynch TJ; Elias AD; Jacobs C; Kwiatkowski DJ; Shulman LN; Carey RW; Grossbard ML; Jauss S; Sugarbaker DJ
    Semin Oncol; 1995 Aug; 22(4 Suppl 9):70-4. PubMed ID: 7544029
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preliminary report on a phase I study of ifosfamide and vinorelbine (navelbine) in advanced non-small cell lung cancer.
    Masters GA; Hoffman PC; Drinkard LC; Watson S; Samuels BL; Golomb HM; Vokes EE
    Semin Oncol; 1996 Apr; 23(2 Suppl 5):11-8. PubMed ID: 8610230
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Etoposide, ifosfamide, and methotrexate combination chemotherapy for aggressive non-Hodgkin's lymphomas after failure of the LNH 84 regimen.
    Herbrecht R; Damonte JC; Dufour P; Maloisel F; Liu KL; Ortiz S; Bergerat JP; Oberling F
    Semin Oncol; 1992 Feb; 19(1 Suppl 1):7-10. PubMed ID: 1384135
    [TBL] [Abstract][Full Text] [Related]  

  • 27. European experience with ifosfamide in lymphomas.
    von Kalle AK; Schaadt M; Diehl V
    Semin Oncol; 1989 Feb; 16(1 Suppl 3):73-7. PubMed ID: 2468184
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia.
    Yamaguchi M; Suzuki R; Kwong YL; Kim WS; Hasegawa Y; Izutsu K; Suzumiya J; Okamura T; Nakamura S; Kawa K; Oshimi K
    Cancer Sci; 2008 May; 99(5):1016-20. PubMed ID: 18294294
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Topotecan plus ifosfamide in patients with platinum refractory advanced/metastatic non-small cell lung cancer: a phase II trial.
    Lorusso V; Gebbia V; Spada M; Guida M; Cassano G; Brunetti C; Germano D; Nettis G; Izzi G; Galetta D; Giampaglia M; Silvestris N; Colucci G
    Oncol Rep; 2005 Dec; 14(6):1547-51. PubMed ID: 16273254
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ifosfamide, etoposide, cytarabine, and methotrexate as salvage chemotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
    Stamatoullas A; Fruchart C; Bastit D; Boulet D; Moncondult M; Piguet H; Tilly H
    Cancer; 1996 Jun; 77(11):2302-7. PubMed ID: 8635099
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy.
    Pels H; Schmidt-Wolf IG; Glasmacher A; Schulz H; Engert A; Diehl V; Zellner A; Schackert G; Reichmann H; Kroschinsky F; Vogt-Schaden M; Egerer G; Bode U; Schaller C; Deckert M; Fimmers R; Helmstaedter C; Atasoy A; Klockgether T; Schlegel U
    J Clin Oncol; 2003 Dec; 21(24):4489-95. PubMed ID: 14597744
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase II study of a high-dose ifosfamide-based chemotherapy regimen with growth factor rescue in recurrent aggressive NHL. High response rates and limited toxicity, but limited impact on long-term survival.
    van Besien K; Rodriguez A; Tomany S; Younes A; Donato M; Sarris A; Giralt S; Mehra R; Andersson B; Gajewski J; Champlin R; Cabanillas F
    Bone Marrow Transplant; 2001 Feb; 27(4):397-404. PubMed ID: 11313669
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Preliminary results of ifosfamide and doxorubicin regimen in treatment of patients with recurrent and metastatic nasopharyngeal carcinoma].
    Huang HQ; Zhou ZM; Li YH; Jiang WQ; He YJ; Teng XY; Guan ZZ
    Ai Zheng; 2002 Apr; 21(4):409-11. PubMed ID: 12452022
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sequential combination of methotrexate and L-asparaginase in the treatment of refractory acute leukemia.
    Amadori S; Tribalto M; Pacilli L; De Laurentis C; Papa G; Mandelli F
    Cancer Treat Rep; 1980; 64(8-9):939-42. PubMed ID: 6934851
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase I study of ifosfamide, paclitaxel, and carboplatin in advanced and recurrent cervical cancer.
    Downs LS; Judson PL; Argenta PA; Carson LF; Boente MP
    Gynecol Oncol; 2004 Nov; 95(2):347-51. PubMed ID: 15491756
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Prognostic analysis of patients with nasal-type NK/T-cell non-Hodgkin's lymphoma--a report of 93 cases].
    Pan ZH; Huang HQ; Lin XB; Xia YF; Xia ZJ; Peng YL; Cai QQ; Lin TY; Jiang WQ; Guan ZZ
    Ai Zheng; 2005 Dec; 24(12):1493-7. PubMed ID: 16351799
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Salvage chemotherapy with a combination of VP-16, ifosfamide, procarbazine, prednisolone, bleomycin and methotrexate (VIPP-BM) for refractory malignant lymphoma].
    Ohnishi K; Hotta T; Murate T; Inoue C; Ichikawa A; Ninomiya N; Goto S; Tsushita K; Utsumi M; Nagura E
    Rinsho Ketsueki; 1989 Mar; 30(3):289-96. PubMed ID: 2475652
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ambulatory administration of 5-day infusion ifosfamide+mesna: a pilot study in sarcoma patients.
    Coriat R; Mir O; Camps S; Ropert S; Billemont B; Leconte M; Larousserie F; Anract P; Alexandre J; Goldwasser F
    Cancer Chemother Pharmacol; 2010 Feb; 65(3):491-5. PubMed ID: 19588140
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pilot study of multiple-fraction daily radiotherapy alternating with chemotherapy in patients with stage IV non-oat cell lung cancer.
    Arcangeli G; Righini R; Nervi C; Guerra A; Tirindelli D; Hopkins H; Looney W
    Cancer Treat Rep; 1985 Jan; 69(1):25-31. PubMed ID: 2981618
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B-cell lymphoma.
    Micallef IN; Kahl BS; Maurer MJ; Dogan A; Ansell SM; Colgan JP; Geyer S; Inwards DJ; White WL; Habermann TM
    Cancer; 2006 Dec; 107(12):2826-32. PubMed ID: 17099879
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.